ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

4.41
-0.07
(-1.56%)
Closed July 20 4:00PM
4.47
0.06
(1.36%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
4.41
Bid
4.30
Ask
11.67
Volume
15,673
4.30 Day's Range 4.60
2.38 52 Week Range 11.99
Market Cap
Previous Close
4.48
Open
4.46
Last Trade
2
@
4.5
Last Trade Time
Financial Volume
$ 70,415
VWAP
4.4927
Average Volume (3m)
90,490
Shares Outstanding
10,758,805
Dividend Yield
-
PE Ratio
-3.01
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-15.96M

About Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was $4.48. Over the last year, Lantern Pharma shares have traded in a share price range of $ 2.38 to $ 11.99.

Lantern Pharma currently has 10,758,805 shares outstanding. The market capitalization of Lantern Pharma is $48.20 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -3.01.

LTRN Latest News

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug...

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.143.278688524594.275.14.21668784.52425452CS
4-0.01-0.2262443438914.425.13.83680914.28162712CS
12-1.14-20.54054054055.557.213.83904905.44084384CS
260.6116.05263157893.811.993.692007746.9330124CS
52-0.49-104.911.992.381178386.47702981CS
156-8.44-65.680933852112.85152.38727197.00010509CS
260-10.75-70.910290237515.1624.842.38769859.89729154CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

LTRN Discussion

View Posts
dinogreeves dinogreeves 3 months ago
Nice drop
🕳️ 1 🪦 1 ⚰️ 1
Monksdream Monksdream 3 months ago
LTRN under $10
👍️0
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
dinogreeves dinogreeves 4 months ago
Monk, take a look at ANV*S. Data is due sometime in April, Parkinsons and Alzheimers. They just did a private placement on Friday and another one today to an institutional investor. "Subject to Certain Conditions". Looks like April is go time.
👍️0
dinogreeves dinogreeves 4 months ago
I think we can revisit the high again hopefully this week. Been here since 7.20
💩 1 🖕🏻 1
spartex spartex 4 months ago
10-K filing, Earnings Webcast, Presentation in link below from LTRN company website


https://ir.lanternpharma.com/news-events/press-releases/detail/150/lantern-pharma-reports-fourth-quarter-fiscal-year-2023
👍️0
Monksdream Monksdream 4 months ago
LTRN new 52 hi
👍️0
dinogreeves dinogreeves 4 months ago
Another very good day today.
👍️0
Monksdream Monksdream 4 months ago
LTRN 10Q due 3/18
👍️0
dinogreeves dinogreeves 4 months ago
Very good move on Friday.
🪦 1 ☠️ 1 ⚰️ 1 ⚱️ 1
dinogreeves dinogreeves 4 months ago
This company will see 3 digit dollars, how soon? All depends on just one science behind their Artificial Intelligence to decode one cancer indication the rest will be history.
👍️0
dinogreeves dinogreeves 4 months ago
This is going to have one heck of a run.
👍️0
Tremors! Tremors! 4 months ago
Will they break 10.00!??
👍️0
Roily23 Roily23 5 months ago
👍️0
Roily23 Roily23 5 months ago
AI is the next .com and AI's application in medicine and pharma will be a game changer.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
👍️0